The European Medicines Agency (EMA) announced on the 19th local time that U.S. pharmaceutical company Merck & Company (MSD)'s oral COVID-19 treatment 'molnupiravir' for the treatment of adults who do not require additional oxygen and who are at risk of developing severe disease. Said it could be used.
The EMA explained that the Drug User Advisory Committee (CHMP) has issued advice on the use of this drug, which is currently not approved in the European Union (EU).
In addition, the EMA has begun reviewing data on 'Paxrovid', a pill-type treatment for COVID-19 developed by US pharmaceutical company Pfizer.
Pfizer's own clinical trials have shown that hospitalizations and deaths are reduced by 89%.
(Photo = VN Express site capture, Yonhap News)